Durand-Zaleski I, Goldfarb B, Blum-Boisgard C, Drüeke T, Kreis H
Département de Santé Publique, Faculté de Médecine Créteil Val de Marne, France.
Nephrol Dial Transplant. 1993;8(4):311-4.
Treatment of the anaemia of predialysis patients with recombinant human erythropoietin (rHuEpo) is likely to become a widely accepted practice during the coming years. We estimated the impact on health care expenditures with the example of the French population of end-stage renal disease patients. Using retrospective data, we calculated the percentage of predialysis patients with advanced chronic renal failure who would be eligible for treatment according to two different criteria based on haemoglobin and clinical condition, the total duration of treatment, and the total amount of rHuEpo delivered. We estimate that the total cost of treating French predialysis patients could vary between 2.2 and 6.5 million Swiss francs, or 50,000 to 140,000 Swiss francs per million population, using rHuEpo dosage from 50 to 150 IU/kg week.
在未来几年，使用重组人促红细胞生成素（rHuEpo）治疗透析前患者的贫血可能会成为一种被广泛接受的做法。我们以法国终末期肾病患者群体为例，估算了其对医疗保健支出的影响。利用回顾性数据，我们根据血红蛋白和临床状况这两个不同标准，计算了晚期慢性肾衰竭透析前患者中符合治疗条件的患者百分比、治疗总时长以及rHuEpo的给药总量。我们估计，使用每周50至150国际单位/千克的rHuEpo剂量，治疗法国透析前患者的总成本可能在220万至650万瑞士法郎之间，即每百万人口5万至14万瑞士法郎。
